Ozempic maker Novo Nordisk downgraded on governance uncertainty and strategic driftProactive Investors • 10/31/25
Two developments Thursday–Eli Lilly's strong quarterly performance and Novo Nordisk's unsolicited $9 billion bid for a startup–show why drugmakers can't get enough of weight lossWSJ • 10/30/25
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On MetseraInvestors Business Daily • 10/30/25
Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker.Barrons • 10/30/25
Novo Nordisk Moves to Outbid Pfizer With Up to $9 Billion Offer for Obesity Drug Developer MetseraWSJ • 10/30/25
Novo Nordisk said to make higher bid for Metsera to challenge Pfizer, Bloomberg News reportsReuters • 10/30/25
1 Incredible Reason to Buy Novo Nordisk Stock (NVO) in November -- or SoonerThe Motley Fool • 10/29/25
Novo Nordisk Shares Fell 5.6% After President Trump Commented on Future Price Cuts for Weight Loss Drugs. Should Investors Be Worried?The Motley Fool • 10/29/25
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to KnowZacks Investment Research • 10/28/25